As pharmaceutical companies continually strive to find new and evolving ways to combat neuropathic and neurological pain, The SMi Group’s 8th Annual Pain Therapeutics Conference once again showcases the new advances within the pharmaceutical industry.

Listen to case studies on novel targets for effective pain relief such as ion channels, CB2 receptors and the purinergic cascade and explore revolutionary strategies for confronting neuropathic pain.

Senior representatives from the top 10 Pharma Companies together with those from pharmaceutical companies that specialise in pain medication will deliver a series of specialised presentations detailing the discoveries and advances they have made over the last 12 months

The continual success of The SMi Group’s Pain Therapeutics Conference stands as proof of its reputation as the leading conference in the field. With this years’ promising to be the most successful, attendance is compulsory in order to keep abreast of developments in this ever-evolving industry.

This is an exceptional occasion to hear presentations from the industry's decision-making experts:

- Dr James Sullivan, Divisional Vice President, Neuroscience Discovery, Abbott Laboratories
- Dr Linda Surh, Director, CEDD Global Regulatory Affairs, GlaxoSmithKline
- Dr Shimon Amselem, Vice President, Pharmaceutical Development, Pharmos Ltd
- Dr Keith Bley, Senior Vice President, Nonclinical R&D, NeurogesX Inc
- Dr Alyson Fox, Global Head, Gastrointestinal Disease Area, Novartis
- Professor Theo Meert, Senior Research Fellow, Therapeutics Area Leader & Biology Head, CNS, Pain & Neurology, Johnson & Johnson
- Dr Liza Leventhal, Principal Research Scientist 1, Neuroscience Discovery Research, Wyeth
- Dr Steve England, Associate Research Fellow, Discovery Biology, Pfizer
- Dr John Connell, Director, Clinical Pharmacodynamics & Project Management, Icon Development Solutions
- Dr Emanuele Sher, Research Advisor, Pain/Migraine Team, Eli Lilly and Company
- Roland Kozlowski, Chief Executive Officer, Lectus Therapeutics
- Dr Edward Kaftan, Principal Research Scientist, Wyeth
- Dr Peter Schafer, Director, Biology, Drug Discovery, Celgene Corporation
- Dr Stephen Pawsey, Director, Medical Affairs, Vernalis
- Dr Helmut Buschman, Research Director, Laboratorios Dr. Esteve

Benefits of Attending:

- GROUNDBREAKING NEW TARGETS for effective pain relief

- SUCCESSFUL AND NOVEL approaches to neuropathic and neurological pain

- NEW AND EVOLVING ANALGESICS in development

- THE RELEVANCE of translational pharmacology to neurological pain


PLUS AN ASSOCIATED HALF-DAY POST-CONFERENCE EXECUTIVE BRIEFING
The Critical Path for the Discovery of New Pain Therapeutics
13th June 2007
In association with NeuroKnowledge & Pharmidex